

SYM POS IUM

ADJUVANT TREATMENT OF MELANOMA

Agenda:

- 15.30 Claus Garbe, Tübingen, Germany Wellcome
- 15.30 Axel Hauschild, Kiel, Germany Adjuvant interferon-alpha treatment: an update
- 15.50 William H. Stimson, Glasgow, UK Interferon-alpha subtypes
- 16.10 John Kirkwood, Pittsburgh, USA Future perspectives of adjuvant treatment



SWEDISH ORPHAN INTERNATIONAL

Drottninggatan 98 SE-111 60 Stockholm Tel: +46 8 412 98 00 www.swedishorphan.com

3RD WORLD MEETING OF INTERDISCIPLINARY MELANOMA/SKIN CANCER CENTERS

NOVEMBER 19-21, 2009 BERLIN, GERMANY, ELLINGTON HOTEL

SYM

THURSDAY NOVEMBER 19 ADJUVANT TREATMENT OF MELANOMA

POS

SWEDISH ORPHAN INTERNATIONAL

CHAIR: CLAUD GARBE, TÜBINGEN, GERMANY

IUM

ADJUVANT TREATMENT OF MELANOMA

SWEDISH ORPHAN INTERNATIONAL

AGENDA:

- 15.30 Claus Garbe, Tübingen, Germany Wellcome
- 15.30 Axel Hauschild, Kiel, Germany Adjuvant interferon-alpha treatment: an update
- 15.50 William H. Stimson, Glasgow, UK Interferon-alpha subtypes
- 16.10 John Kirkwood, Pittsburgh, USA Future perspectives of adjuvant treatment

SYM POS IUM

ADJUVANT TREATMENT OF MELANOMA




SWEDISH ORPHAN
INTERNATIONAL

INTRO

Ucianimpor aut est aut magnitas dolum, officimag-
nis reicate voluptatusci quia pra natis rendit apien-
dis resed quod quo quis apitas exerio mo quam,
conessi atia velit od qui totam ad eaquas deliass
itibeaq uatium nescium ipsam is repero cus autem-
pore, esto bla iuntus acerior unturesserit officabo.
Ed quo cumquam autem. Ucid maximi, sedici sint
por aut officipici veri blanden debitis rectet por restis
quibus es es siminvete modisim et rem dolor apicae
volo ium iuntur sant, te dundiciet ist, si sollore rsperit
venimenetur, consequist volo mos erchit, quo offic
qui ducia sim vel ides aut faci unt dicimetur sitiam, et
aut quibusam natio te di renatur?

Abor re prem etur sita porerum del idelis sandita sim
et laces voloria nobis et rem fugiam que as event
earum necae labore, test, totas acerias apellectum
ilistia dolo que ommolorates es aut adignissecae
invendunt elest, conse veratiam, nobis res aut eve-
lect ecabo. Natem am dist, quo il ent, arunti a dit,
idi nus sit quia et, con porem non renam, corepti
temperovit, comnisiti dusdae sit ma sitiist orerore
moluptibus eos maximag



CURRICULUM VITAE

CLAUS GARBE, MD PhD

Dr. Garbe is Professor of Dermatology at Eberhard-Karls-University in Tübingen, Head of the Division of Dermatologic Oncology at the University Medical Centre, Head of the German Central Malignant Melanoma Registry, and Vice-President of the European Association of Dermato-Oncology (EADO). In addition, he has served as principle investigator on numerous multicenter clinical trials and directed laboratory research in cellular and molecular biology. Dr. Garbe has also participated in organization of several major international scientific meetings and serves as a Scientific Board Member of the World Conference on Melanoma and the International Congress on Cancers of the Skin. Dr. Garbe's research interests include general biology and genetics of melanoma, new therapeutic approaches in treatment of skin diseases, and large clinical and epidemiological studies in melanoma. He has published 435 articles, including 329 articles in peer-review journals, and 16 science text books.

CURRICULUM VITAE

AXEL HAUSCHILD, MD

Dr. Hauschild is a professor and head of Dermato-Oncology and Dermatologic Surgery as well as a senior consultant dermatologist for the Department of Dermatology, University Hospital Schleswig-Holstein at Kiel, Germany. He is board certified in dermatology and venerology, allergology, phlebology, and dermatology. He is president of the Dermatologic Cooperative Oncology Group (DeCOG) and a board member of the European Association of Dermatologic Oncology (EADO) as well as several other national and international organizations. Dr. Hauschild has the distinction of being the principal investigator of 42 clinical studies in the areas of melanoma, cutaneous lymphoma and epithelial skin cancer, among others. He is on the editorial boards of 19 scientific journals on oncology and dermatology and has given more than 350 national and international scientific lectures. He has published more than 120 peer-reviewed articles, and 70 others articles, and contributed to more than 50 books in his fields of expertise.

CURRICULUM VITAE

JOHN KIRKWOOD, MD

John Munn Kirkwood is M.D. at Division of Medical Oncology, Department of Medicine, University of Pittsburgh. In addition he is Professor and Vice Chairman for Clinical Research, Department of Medicine, School of Medicine Pittsburgh, PA and Director of Melanoma Center at University of Pittsburgh Cancer Institute. Dr. Kirkwood has memberships in 11 professional and scientific societies. Beside this Dr. Kirkwood has got 26 honors so as The Best Doctors in America from 2002-2009; Melanoma Research Foundation Wings of Hope Award, New York, NY; European Award of Interferon and Cytokine Research, Hannover, Germany and Wade Waddell Prize for Research (U. Arizona). Dr. Kirkwood's research interests include Analysis of the immune response to melanoma and its impact upon disease relapse and course; Analysis of the features/determinants of progression in melanoma; Determination of mechanisms of interferons, antibodies, and vaccines in the therapy of advanced and high-risk patients with solid tumors and Identification of new tumor antigens and new potential diagnostic/therapeutic avenues based upon new tumor antigens. Dr. Kirkwood has published 251 articles; 164 Reviews, Invited Published Papers, Proceedings, Editorials, Letters, Books and Book Chapters; 202 Published Abstracts and 3 Other Publications.

CURRICULUM VITAE

WILLIAM H. STIMSON

William H Stimson is Professor of Immunology, Division of Immunology, Microbiology and Biochemistry, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde. Immunology gained the top 5* Grade in the 1996/2002 Government Research Assessment Exercises. In addition he has following Fellowships: 1985 Institute of Biology (CBiol, FIBiol); 1986 Royal Society of Edinburgh (FRSE); 1998 Institute of Nanotechnology (FloN); 2001 World Innovation Foundation (FWIF).

Professor Stimson's significant information includes Journal Editorial Boards – 5; Chairman of the Trustees and Advisory Board Member, Institute of Nanotechnology, UK and UK NanoMedicine Committee; Published more than 210 scientific papers and 18 patents; Consultant to 5 multinationals on a long term basis (e.g. Akzo Nobel – 19 years, Rhone Poulenc Ltd – 13 years); Directorships held – Rhone Poulenc Ltd, Monotech Laboratories Ltd., MDC Learning Systems Ltd., Viragen International Inc., Viragen (Scotland) Ltd., Viranative Se, PhytoCorp Ltd, Solus Biologicals and Scientific Solutions Ltd. and the Institute of Nanotechnology.

CURRICULUM VITAE

SYMPOSIUM

ADJUVANT TREATMENT OF MELANOMA

Adjuvant treatment of melanoma
melanoma

Adjuvant treatment of melanoma
melanoma

Adjuvant treatment of melanoma
melanoma

Adjuvant treatment of melanoma
melanoma

Adjuvant treatment of melanoma
melanoma

Adjuvant treatment of melanoma
melanoma
